



CASE STUDY

Comparing outcomes among patient treatment options using the claims database

Optum evaluated data related to chronic obstructive pulmonary disease (COPD) patients receiving treatment using either the long-acting muscarinic antagonist/long-acting β 2-agonist (LAMA/LABA) therapy or the LAMA monotherapy option.

Client objectives

- Understand the difference in outcomes for COPD patients receiving a combination therapy versus the monotherapy option in relation to triple escalation.
- Confidently advise treatment benefits to varying patient populations.
- Better inform safety profiles to the disparity among therapy options.

Project details

- A retrospective study was performed for a cohort of COPD patients, using medical and pharmacy data from the Optum® Research Database.
- Patients were identified based on age and enrollment in a U.S.-based medical plan.
- Identification also included being newly initiated to a COPD treatment with continuous 12-month enrollment.
- Patients that opted for use of the LAMA therapy were matched by a 1:1 propensity score to those who used LAMA/LABA.
- Triple therapy (TT) initiation rates were reported among users by comparing Rx claims.

Results

This study confirms the hypothesis that patients who participate in the LAMA/LABA combination treatment escalate to TT at a much slower rate than the patients that participate in the LAMA monotherapy treatment.

Source:

Hahn B, Hull M, Blauer-Peterson C, Buikema AR, Ray R, Stanford RH. Rates of escalation to triple COPD therapy among incident users of LAMA and LABA/LAMA. *Respiratory Medicine*. 2018. doi: 10.1016/j.rmed.2018.04.014.

11000 Optum Circle, Eden Prairie, MN 55344

Optum® is a registered trademark of Optum, Inc. in the U.S. and other jurisdictions. All other brand or product names are the property of their respective owners. Because we are continuously improving our products and services, Optum reserves the right to change specifications without prior notice. Optum is an equal opportunity employer.

© 2018 Optum, Inc. All rights reserved. WF745757 07/18